Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount raised topping $331 million.
Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, hoping to raise funds for inflammatory respiratory disease therapy verekitug.
Further signs that the biotech initial public offering (IPO) market is picking up have come with a filing by MBX Biosciences, seeking around $100 million to take a hypoparathyroidism candid
